Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Cancer

Exclusion Criteria

• •Patients who meet any of the following criteria will be excluded from the study:
• •1. Recurrence of primary tumor
• •2. Severe arterial embolism or ascites
• •3. A tendency to bleed or clotting disorder
• •4. Hypertensive crisis or hypertensive encephalopathy
• •5. Severe uncontrolled systemic complications such as infection or diabetes
• •6. Clinically serious cardiovascular diseases such as cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), uncontrolled hypertension after appropriate drug treatment, unstable angina, congestive heart failure (nyha2-4), and arrhythmia requiring drug treatment
• •7. History of central nervous system disease (e.g. primary brain tumor, epilepsy beyond the control of standard treatment, any brain metastasis or stroke)
• •8. Other malignancies in the past 5 years (except basal cell carcinoma of skin and/or cervical carcinoma in situ after radical resection)
• •9. Received any drug under study or treatment with the same type of drug in the last 28 days before the study
• •10. Any residual toxicity from previous chemotherapy (except hair loss), such as peripheral neuropathy ≥NCI CTC v3.0 standard level 2
• •11. Is allergic to any of the drugs in the study
• •12. Pregnant and lactating women
• •13. Inability or unwillingness to comply with research protocols
• •14. The presence of any other disease, dysfunction due to metastatic lesions, or a suspected medical condition indicated a possible contraindication to the use of the study drug or a population at high risk for treatment-related complications